As of June 30, 2026, Ascletis Pharma, Inc. carries a market capitalization of 1.25B, placing it among publicly traded companies globally. Its enterprise value stands at 960.38M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.25B |
| Enterprise Value | 960.38M |
Ascletis Pharma, Inc.'s next confirmed earnings release is scheduled for March 30, 2027.
| Earnings Date | 3/30/2027 |
As of June 30, 2026, Ascletis Pharma, Inc. has 1.06B shares outstanding.
| Shares Outstanding | 1.06B |
These figures are as of June 30, 2026.
| PB Ratio | 4.27 |
| P/TBV Ratio | 4.29 |
As of June 30, 2026, Ascletis Pharma, Inc. maintains a current ratio of 12.92, meaning it holds 12.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.92 |
| Quick Ratio | 12.76 |
| Debt / Equity | 0.16 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 202.00 |
As of the close on November 17, 2026, Ascletis Pharma, Inc.'s stock has declined approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.77, while the 200-day moving average is 1.28.
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 1.28 |
As of June 30, 2026, Ascletis Pharma, Inc. holds 292.52M in cash and equivalents against 481,991.69 in total debt, resulting in a net debt position of -76.55M. Total book value stands at 292.98M, with working capital of 273.13M providing operational flexibility.
| Cash & Cash Equivalents | 292.52M |
| Total Debt | 481,991.69 |
| Net Debt | -76.55M |
| Equity (Book Value) | 292.98M |
| Book Value Per Share | 0.28 |
| Working Capital | 273.13M |
Already premium?